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Hyperinsulinaemia due to inhibition of 5a-reductases is ameliorated by
liver-selective glucocorticoid receptor antagonism in diet-induced
obesity
Tracy C S Mak, Dawn E W Livingstone, Brian R Walker & Ruth Andrew
University of Edinburgh, Edinburgh, UK.
Background
5a-reductase 1 (5aR1) metabolises steroids such as glucocorticoids and
androgens, and is highly expressed in murine liver. Genetic disruption of 5aR1
leads to adverse metabolic changes in mice. We hypothesised that dutasteride, a
5aR inhibitor, induces insulin resistance in mice, as in humans, and this effect is
underpinned by increased hepatic glucocorticoid action; an experimental
paradigm was set up using A-348441, a liver-selective glucocorticoid receptor
(GR) antagonist, and then utilised to assessed the contribution of increased
hepatic glucocorticoid action to the metabolic consequences of dutasteride.
Methods
C57BL6/J male mice (nZ8–15/group; age 12 weeks) were given high fat (HF),
HF with A-348441 (KaroBio), HFCdutasteride (Dut), or HFCDutCA-348441
diet for 4 weeks. Glucose tolerance tests (GTT) were performed at week 3, with
mice culled at week 4. Plasma insulin and corticosterone were measured by
ELISA and plasma glucose spectrophotometrically. Data are meanGS.E.M.,
#P!0.05 vs HF diet and $P!0.05 vs HFCDut diet.
Results
Plasma corticosterone concentrations were not changed by A-348441, supporting
liver-selective GR antagonism. A-348441 improved metabolic health of mice
receiving a HF diet, preventing HF-induced bodyweight gain (34.3G0.5 g vs
31G0.8 g#), and total white adipose depot weight gain (2.46G0.1 g vs 1.58G
0.1 g#), and attenuating HF-induced elevations in fasting plasma insulin, fasting
glucose and insulin response to GTT (lowered by 52#, 25#, and 44%# respectively)
. Inhibition of 5aRs with dutasteride impaired insulin sensitivity, with increased
insulin response to GTT but did not change body weight, total adipose depot
weight, fasting insulin, fasting glucose, or glucose response to GTT; A-348441
reduced this hyperinsulinaemia (235.9G17 ng/ml per min vs 329.3G16# ng/ml
per min vs 198.4G25$ ng/ml per min).
Conclusions
Liver-specific GR antagonism ameliorates the metabolic consequences of acute
diet-induced obesity. Hyperinsulinaemia caused by inhibition of 5aRs was
ameliorated by A-348441, suggesting that hepatic glucocorticoid action plays a
substantial role in metabolic dysfunction caused by 5aR inhibition. Moreover,
targeting hepatic GR may be beneficial in maintaining metabolic homeostasis in
diet-induced obesity.
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Glucagon increases energy expenditure independently of brown adipose
tissue activation in humans
Chioma Izzi-Engbeaya1, Victoria Salem1, Rajveer Atkar1,
Christopher Coello2, David Thomas3, Alexander Comninos1,
Adam Buckley1, Eugenii Rabiner2, Roger Gunn2, Tricia Tan1,
Stephen Bloom1 & Waljit Dhillo1
1Section of Investigative Medicine, Imperial College London, London, UK;
2Imanova Imaging Centre, London, UK; 3Department of Computing,
Imperial College London, London, UK.
Background
Obesity is a global health concern. Elevating energy expenditure (EE) would be a
highly effective treatment approach to treat obesity but no current drugs can safely
achieve this. Cold exposure potently increases EE through brown adipose tissue
(BAT) thermogenesis in humans. Glucagon elevates EE via BAT in rodents but
the mechanism in humans is unknown. We investigated for the first time the
mechanism by which glucagon increases EE in humans.
Methods
Eleven volunteers underwent measurement of EE using an indirect calorimeter at
the start and end of three interventions: i) cold exposure; ii) control (vehicle)
infusion at 23 8C; and iii) glucagon infusion at 23 8C. On each visit thermal
images of the neck were taken – an increase in temperature is a non-invasive
measure of increased BAT activity. All 11 volunteers also underwent a FDG
PET–CT scan with cold exposure. In those in which this confirmed cold-induced
BAT activity (nZ8), they had a second PET–CT scan with either vehicle (nZ4)
or glucagon (nZ4) infusion (23 8C).
Results
EE rose by 14% with cold exposure and 15% following glucagon infusion
(P!0.05 vs control). BAT depots identified on the cold scan had significantly
(4!) higher metabolic activity than on the vehicle or glucagon infusion scans,
which were not significantly different from each other. There was a 0.31 8C rise
(P!0.001) in neck temperature on thermal images after cold exposure in the BAT
positive cohort but not after glucagon or vehicle infusion.
Conclusions
Glucagon and cold exposure have a similar effect in stimulating energy
expenditure but glucagon has no effect on the metabolic activity of classical
adult supraclavicular BAT compared with cold exposure. This information is of
importance to the development of better targeted and safe treatments designed to
combat obesity through upregulation of energy expenditure.
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Cardiac fibrosis and the balance between glucocorticoid and
mineralocorticoid receptors signalling
Rachel Richardson1,2, Emma Batchen1, Rowan Darroch1,
Kathleen Scullion1, Ewa Rog-Zielinska1,3, Christopher Kenyon1,
Gillian Gray1 & Karen Chapman1
1University of Edinburgh, Edinburgh, UK; 2Newcastle University,
Newcastle, UK; 3Imperial College London, London, UK.
Specific variations in the human glucocorticoid receptor (GR) gene associate with
increased cardiovascular disease risk. GR signalling is essential for cardiac
maturation in utero and adult mice with cardiomyocyte and vascular smooth
muscle deletion of GR (SMGRKO mice) have cardiac hypertrophy, fibrosis and
impaired function. Intriguingly, levels of left ventricle (LV) mRNA encoding the
mineralocorticoid receptor (MR), which is pro-fibrotic in heart, rise postnatally in
SMGRKO mice in parallel with the development of cardiac fibrosis. Here, the
benefit of MR antagonism in limiting cardiac fibrosis was assessed in SMGRKO
mice.
SMGRKO mice (generated via SM22a-Cre mediated deletion of GR) and control
(CreK) littermates were treated from birth with vehicle or 20 mg/kg per day
spironolactone, an MR antagonist, administered in the drinking water to lactating
dams until weaning then to offspring (nZ10–13/group). At 8 weeks of age, hearts
were collected for histology and mRNA profiling. Data were analysed by two-
way ANOVA with Tukey’s multiple comparisons test.
Heart weight in male SMGRKO mice was higher than controls irrespective of
spironolactone treatment (P!0.01). Interestingly, spironolactone modestly
reduced heart weight in both genotypes (P!0.05).
PicroSirius Red staining showed greater collagen levels in LV of SMGRKO mice
(P!0.001); spironolactone treatment reduced the magnitude of this genotypic
difference. Although spironolactone did not prevent the increase in LV levels of
mRNA encoding MR or profibrotic factors (connective tissue growth factor,
collagen1a2 and collagen3a1) in SMGRKO mice, it did attenuate collagen1a2
mRNA increases (P!0.05).
In conclusion, the modulatory effects of spironolactone on pro-fibrotic signalling
suggest that elevated MR contributes to the pro-fibrotic cardiac phenotype
discovered in SMGRKO mice. Consequently, MR antagonism may benefit
individuals with particular variants of the GR gene. Spironolactone effects on
heart weight indicate a role for MR in early life cardiac growth and SMGRKO
mice are, potentially, a useful new model to investigate MR-dependent cardiac
fibrosis.
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Functional consequences of germline mutations in a novel non-RET
medullary thyroid cancer susceptibility gene
Martin Read1, Joel Smith1, Vicki Smith1, Emy Bosseboeuf1, Naomi Wake1,
John Watkinson1,2, Yvonne Wallis1,3, Eamonn Maher1,4,
Christopher McCabe1 & Emma Woodward1,3
1Centre for Endocrinology, Diabetes and Metabolism, Institute of
Metabolism and Systems Research, University of Birmingham,
Birmingham, UK; 2University Hospitals Birmingham NHS Foundation
Trust, Birmingham, UK; 3Birmingham Women’s NHS Foundation Trust,
Birmingham, UK; 4Department of Medical Genetics, University of
Cambridge, Cambridge, UK.
Whilst the majority of familial medullary thyroid cancer (MTC) is caused by
germline mutations of the RET proto-oncogene, there are families and individuals
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with predisposition to MTC in whom no RET mutation has been identified (non-
RET MTC). Recently, we identified novel mutations in a single gene termed
MTC2 in non-RET MTC individuals by whole exome sequencing. The precise
role of these MTC2 germline mutations in MTC tumorigenesis is however
unclear. Here, we examined the functional consequences of MTC2 mutants
V128L and G318Afs*22 to determine their roles in MTC. Luciferase (LUC)
reporter assays showed that MTC2-V128L retained transcriptional activity with a
significant increase in LUC activity in response to steroid hormone receptor-
agonist DPN in HCT116 (3.7-fold; P!0.01) and MCF-7 (1.8-fold; P!0.05)
cells. In contrast, MTC2-G318Afs*22 was incapable of inducing LUC activity in
either cell line (PZNS). Furthermore, MTC2-G318Afs*22 failed to inhibit ERa-
driven luciferase activity in response to either 17b-estradiol (E2) or ERa-agonist
PPT, or restrain ERa-driven proliferation of MCF7 cells (PZNS compared to
ERa alone). In contrast, WT MTC2 and MTC2-V128L inhibited ERa-driven
LUC activity (O60%; P!0.01) and cell proliferation (O30%; P!0.05). As RET
expression is known to be stimulated by oestrogen, we then determined the
influence of MTC2 mutants on RET in E2- and PPT-treated HCT116 cells. In
contrast to WT MTC2, MTC2-G318Afs*22 was unable to oppose ERa-
stimulation of the RET proto-oncogene at both the mRNA and protein level
(PZNS compared to ERa alone). Treatment with anti-oestrogen
4-hydroxytamoxifen was however capable of inhibiting E2-induced RET
mRNA expression in cells with MTC2-G318Afs*22. Together these data indicate
an emerging role for MTC2 as a novel susceptibility gene in non-RET MTC
development, especially as MTC2 mutant G318Afs*22 was associated with
higher RET levels. These results also suggest that anti-oestrogens might represent
a promising therapeutic strategy for MTC individuals with defective MTC2.
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A novel, missense, mutation (P81R) in the TRH receptor gene in
congenital central hypothyroidism
Olympia Koulouri1, Adeline Nicholas1, Erik Schoenmakers1,
Jacek Mokrosinski1, Frances Lane2, Trevor Cole2, Jeremy Kirk3,
Sadaf Farooqi1, Krishna Chatterjee1, Mark Gurnell1 &
Nadia Schoenmakers1
1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of
Metabolic Science, Addenbrooke’s Hospital, University of Cambridge,
Cambridge, UK; 2West Midlands Regional Genetics Service, Birmingham
Womens Hospital NHS Foundation Trust, Birmingham, UK; 3Department
of Endocrinology, Birmingham Children’s Hospital, Birmingham, UK.
Background
Congenital, isolated, central, hypothyroidism (CCH), is rare and evades diagnosis
on TSH-based congenital hypothyroidism screening programmes in the UK.
Genetic ascertainment is therefore paramount in enabling prompt diagnosis and
treatment of familial cases. Recognised causes include TSHB and IGSF1 gene
defects, with only two previous reports of biallelic, highly disruptive (nonsense;
R17X, in-frame deletion and missense; p.S115-T117delCT118), mutations in the
TRHR gene. Here, we describe the first homozygous missense mutation in TRHR,
associated with a typical phenotype.
Case
A female infant from a consanguineous Pakistani family, presented with
prolonged neonatal jaundice and was found to have central hypothyroidism
(TSH 2.2 mU/l, NR 0.4–3.5 and free T4 7.9 pmol/l, NR 10.7–21.8), with
otherwise normal pituitary function. With TSHB or IGSF1 mutations being
usually associated with profound or X-linked CCH, a TRHR mutation was sought.
Results
Sequencing identified a homozygous mutation (P81R) in TRHR, substituting
arginine for a proline residue in transmembrane helix 2 (TM2) which is highly
conserved amongst G-protein coupled receptors (GPCRs). Functional studies
showed that although the mutant receptor was expressed and localised to the cell
membrane normally, its ability to bind radiolabelled TRH and signal via Gqa was
markedly impaired, likely due to disruption of structure of TM2.
Conclusion
We describe the first deleterious, missense TRHR defect associated with moderate
CCH. Importantly, the location of the mutated amino acid (proline 81) highlights
a previously unanticipated functional importance of the TM2 in mediating
hormone binding and receptor activation. Future identification of other, naturally-
occurring, TRHR mutations may map the molecular basis of ligand binding and
activation of TRHR which are poorly understood.
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Use of 11C-methionine PET to localise parathyroid
adenoma/hyperplasia: a single centre experience
Ben Challis2, Ziauddin Saad1, H K Cheow1, John Buscombe1 &
Helen Simpson1
1Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK;
2University of Cambridge, Cambridge, UK.
Introduction
It is established practice to localise parathyroid lesions preoperatively using
ultrasound (US) and sestaMIBI (MIBI). Whilst these imaging techniques have
good sensitivity/specify, there are patients in which imaging does not localise a
parathyroid lesion. 11C-Methionine PET (MET PET) is an imaging modality
where 11C-methionine, a radioactive tracer, is taken up at sites of protein/peptide
synthesis and has been demonstrated to be effective in localising parathyroid
lesions. We therefore investigated the clinical utility of this imaging technique at
our centre.
Methods
All patients had biochemistry prior to imaging thought to be consistent with
primary hyperparathyroidism. Criteria to undergo PET imaging were inability of
conventional imaging to identify a parathyroid lesion, potential intrathyroidal
parathyroid lesion, and three patients where mediastinal disease was suspected.
Twenty patients underwent MET PET over an 18-month period.
Results
MET PET identified a parathyroid lesion in 14/20 patients. Three out of three of
these were demonstrated to be mediastinal lesions, leading to a parathyroid
adenoma being successfully resected by sternotomy. 11/20 demonstrated disease
in the neck. Of these 3/11 parathyroid lesions were very deep in the neck adjacent
to vertebrae/oesophagus and not seen with US/sestaMIBI. In 2/11 patients MET
PET demonstrated intrathyroidal parathyroid lesions and patients underwent
hemithyroidectomy. All parathyroid lesions were confirmed on histology (13
adenoma and one hyperplasia). Of the 6/20 who had negative imaging, one now
has a diagnosis of sarcoidosis with elevated 1,25-dihydroxycholecalciferol, one
underwent bilateral neck exploration and histology demonstrated parathyroid
hyperplasia. The remaining four patients are still being investigated with working
diagnoses of FHH in three patients.
Discussion
MET PET is a useful additional functional imaging technique when conventional
imaging fails to localise a lesion, where mediastinal disease is suspected or
intrathyroidal disease needs confirmation. This can particularly helpful when
deciding to refer patients for major surgery.
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A novel modulator of cellular invasion and metastasis in endocrine
cancer
Rachel Watkins1, Waraporn Imruetaicharoenchoke1, Neil Sharma1,
Erica Gentillin2, Emy Bosseboeuf1, Perkin Kwan1, Rachel Fletcher1,
Hisham Mehanna1, Kristien Boelaert1, Martin Read1, Vicki Smith1 &
Christopher McCabe1
1University of Birmingham, Birmingham, UK; 2University of Ferrara,
Ferrara, Italy.
Metastasis is a multistep process responsible for the majority of endocrine cancer
deaths. Central to the ability of cells to move is the recruitment of actin fibres at
the periphery of the cell by key proteins, especially the cortical actin binding
protein cortactin. A full understanding of cortactin function is required in order to
address metastatic cell activity within endocrine cancer. We used IP-MS to
discover protein binding partners, and now identify the proto-oncogene PBF as a
new functional binding partner of cortactin, whose expression has recently been
correlated with thyroid and breast cancer metastasis, and with colon cancer extra-
mural vascular invasion. We show that cortactin and PBF interact and co-localise
through immunofluorescence and Proximity Ligation Assays, and that this occurs
within or close to the plasma membrane, and preferentially at the leading edge of
migrating cells. Oncogenic expression of PBF induced potent cell invasion and
migration in thyroid TPC-1 (PZ0.01), breast MCF-7 (P!0.001) and colorectal
HCT116 cells (P!0.001), which was entirely abrogated by the knockdown of
cortactin expression. In nZ43 matched papillary thyroid cancers, cortactin was
significantly upregulated at the mRNA (PZ0.022) and protein (PZ0.045) levels,
particularly in more aggressive tumours, and significantly correlated with PBF
expression. We also demonstrate the interaction between PBF and cortactin
through co-immunoprecipitation assays and reveal that artificially targeting PBF
to the plasma membrane results in increased cortactin binding, entirely blocking
endogenous cellular invasion. Thus, we identify a new modulator of cortactin
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